A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: awaiting (67), pending (44)

MyelomaVCD(SC21)Bortezomib(SC)CyclophosphamideDexamethasone21dayVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-21) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (21 day) Regimen Multiple Myeloma – VCD (SC-2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDSC21BortezomibSCCyclophosphamideDexamethasone21dayVer1.pdf

MyelomaVCD(IV28)Bortezomib(IV)CyclophosphamideDexamethasone28dayVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-28) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (28 day) Regimen Multiple Myeloma – VCD (IV-2
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVCDIV28BortezomibIVCyclophosphamideDexamethasone28dayVer1.pdf

Myeloma VCD (SC35) bortezomib (SC) cyclophosphamide dexamethasone 35 day

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (SC-35) - BORTEZOMIB (SC)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (SC-3
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-SC35-bortezomib-SC-cyclophosphamide-dexamethasone-35-day.pdf

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (IV-3
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Nivolumab Ver 1.1 skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable or metastatic) melanoma in adults WH
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its marketing auth
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its marketing auth
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Sorafenib version 1.1

Description
Chemotherapy Protocol LIVER SORAFENIB This protocol may require funding Regimen  Hepatocellular carci
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Sorafenib-version-1.1.pdf

Capecitabine 1250 (14)

Description
Chemotherapy Protocol BREAST CANCER CAPECITABINE 1250 (14 day) Regimen • Breast Cancer – Capecitabine 1250 (14 day) Indication • Treatment of locally
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine1250-14.pdf

Capecitabine 1000 (14)

Description
Chemotherapy Protocol BREAST CANCER CAPECITABINE 1000 (14 day) Regimen • Breast Cancer – Capecitabine 1000 (14 day) Indication • Treatment of locally
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine1000-14.pdf
211 to 220 of 1000
Previous … 20 21 22 23 24 … Next